Advanced materials:新技术查肝病早期迹象最多用45分钟

2018-05-27 欧飒 新华社微特稿

英国和美国研究人员联合开发一种简单可行的肝病早期诊断技术,用时30至45分钟,有助于防止肝病发展到致命地步。

英国和美国研究人员联合开发一种简单可行的肝病早期诊断技术,用时30至45分钟,有助于防止肝病发展到致命地步。

参与研究的伦敦大学学院教授威廉·罗森伯格说,肝病的主要问题是“无临床症状”,等觉察时往往为时已晚,无法逆转损伤。肝纤维化程度标志着肝受损程度。

英国伦敦大学学院和美国阿默斯特马萨诸塞大学联合组成的研究小组设计出一种感应器,包含外涂荧光剂的大分子。健康人群、肝纤维化早期患者和晚期患者血液中的蛋白质遇到这种大分子,能使荧光剂呈现不同颜色和亮度。用这种感应器验血只需采集指血那么少的血量,成本低,步骤简单。

实验结果显示,用这种感应器验血区分健康人群和肝纤维化患者的准确率为80%,区分轻中度肝纤维化和严重肝纤维化的准确率为60%。研究人员说,他们会改进这种检测肝纤维化的技术,提高准确率,希望有朝一日把它应用于日常检查。

研究报告由《先进材料》发表。

原始出处:

William J. Peveler, Ryan F. Landis, Mahdieh Yazdani, et.al. A Rapid and Robust Diagnostic for Liver Fibrosis Using a Multichannel Polymer Sensor Array. Advanced materials 24 May 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1903802, encodeId=40d0190380277, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Jul 31 16:33:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020052, encodeId=1aad2020052f7, content=<a href='/topic/show?id=8544202eff' target=_blank style='color:#2F92EE;'>#Advanced#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2027, encryptionId=8544202eff, topicName=Advanced)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Jul 30 15:33:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319552, encodeId=79ac31955221, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue May 29 06:41:33 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319114, encodeId=be1d31911422, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Sun May 27 18:20:12 CST 2018, time=2018-05-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1903802, encodeId=40d0190380277, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Jul 31 16:33:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020052, encodeId=1aad2020052f7, content=<a href='/topic/show?id=8544202eff' target=_blank style='color:#2F92EE;'>#Advanced#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2027, encryptionId=8544202eff, topicName=Advanced)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Jul 30 15:33:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319552, encodeId=79ac31955221, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue May 29 06:41:33 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319114, encodeId=be1d31911422, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Sun May 27 18:20:12 CST 2018, time=2018-05-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1903802, encodeId=40d0190380277, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Jul 31 16:33:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020052, encodeId=1aad2020052f7, content=<a href='/topic/show?id=8544202eff' target=_blank style='color:#2F92EE;'>#Advanced#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2027, encryptionId=8544202eff, topicName=Advanced)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Jul 30 15:33:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319552, encodeId=79ac31955221, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue May 29 06:41:33 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319114, encodeId=be1d31911422, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Sun May 27 18:20:12 CST 2018, time=2018-05-27, status=1, ipAttribution=)]
    2018-05-29 yfjms

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1903802, encodeId=40d0190380277, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Jul 31 16:33:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020052, encodeId=1aad2020052f7, content=<a href='/topic/show?id=8544202eff' target=_blank style='color:#2F92EE;'>#Advanced#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2027, encryptionId=8544202eff, topicName=Advanced)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Jul 30 15:33:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319552, encodeId=79ac31955221, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue May 29 06:41:33 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319114, encodeId=be1d31911422, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Sun May 27 18:20:12 CST 2018, time=2018-05-27, status=1, ipAttribution=)]
    2018-05-27 紫迎馨

    关注

    0

相关资讯

BIOMED OPT EXPRESS :心脏病患者的福音:心脏修复新技术将实现应用!

研究人员开发了一种捕捉心脏组织详细生物力学特性的新方法。高分辨率的光学技术填补了开发和测试治疗的重要技术空白,这些疗法可能最终被用于治疗心脏病发作后的心脏损伤。

光束替代心脏手术期间的血液测试

中佛罗里达大学的科学家 Aristide Dogariu 发明了一种使用光线连续监测手术患者血液的方法,首次在生死操作中提供实时状态。该方法已在《自然·生物医学工程》发表。该技术使用光纤机器将光线穿过患者的血液并解释反弹的信号。 研究人员认为,在某些情况下,它可以取代医生抽血和检测患者血液的环节。“该技术在重症监护环境中具有潜力,它可以成为挽救各种其他疾病的危重患者的生命的一部分,”儿科心脏外科主

Journal of the American Chemical Society:为什么药物不能到达癌细胞:研究人员开发新技术来提供答案

对于癌症患者来说,理解治疗成功的几率是令人困惑的。同样的药物,应用于同一类型的癌症患者,有的患者可痊愈,而有的患者却无效。医生常常无法解释原因。现在,多伦多大学的研究人员开始明白其中的一个原因。生物医学工程专业的学生Abdullah Syed和Shrey Sindhwani,以及生物医学工程研究所(IBBME)的同事们,发明了一种技术,可以观察进入肿瘤的纳米颗粒--揭示了阻碍靶向递送的障碍和癌症之

世界帕金森日:新技术带来新希望

今日(4月11日)是第22个世界帕金森日,全球有一半以上的帕金森病人在我国,总数已接近300万,每年都新增超过10万名帕金森患者,而且近年来帕金森病正呈现低龄化趋势。

《福布斯》:利用新技术实现医疗变革,中国已超越西方国家

在世界各国,远程医疗都被作为医疗保健可及性问题的解决方案而广泛提及,然而在美国等西方发达国家,远程医疗的接受程度却差强人意。但《福布斯》认为中国具有做远程医疗的先天土壤:中国消费者对同医生当面问诊期望值极低,而远程医疗则能提供相对比较长时间的问诊服务。

陈昶教授:上海肺科医院在肺部小结节领域的新思路和新技术

肺部小结节是临床常见的问题,在肺癌筛查项目广泛实施后更常见。目前华东胸外联盟肺小结节会议已走到第三届,肿瘤资讯有幸邀请到本次大会主席、上海市肺科医院陈昶教授来回顾和总结这一系列会议的收获。